Business
iFabric Announces Publication of Groundbreaking Clinical Trial Proving the Infection Control Ability of Protx2(R) And Ecopel(TM) Treated Scrubs
MARKHAM, ON / ACCESS Newswire / August 19, 2025 / iFabric Corp. (TSX:IFA)(OTCQX:IFABF), is ple...
About this update from Ifabric Corp.
[{"type":"text","content":"iFabric Announces Publication of Groundbreaking Clinical Trial Proving the Infection Control Ability of Protx2(R) And Ecopel(TM) Treated ScrubsMARKHAM, ON / ACCESS Newswire / August 19, 2025 / iFabric Corp. (TSX:IFA)(OTCQX:IFABF), is pleased to announce that the results of its clinical trial, \"Antimicrobial-treated fabric scrubs can prevent pathogen proliferation on scrubs\", has been officially published in the Journal of Hospital Infection, the editorially independent scientific publication of the Healthcare Infection Society. The aim of the Journal is to publish high quality research and information relating to infection prevention and control that is relevant to an international audience.The study-conducted by subsidiary Intelligent Fabric Technologies (North America) Inc. \"IFTNA\" at MemorialCare Saddleback Medical Center in Southern California under the leadership of Cheryl Westlake, PhD, RN, ACNS-BC, FHFSA, FAHA, FAAN; Kathleen M. Young, MSN, RN, NPD-BC; Brandi Cassingham, MSN, RN; and Lisa Forsythe, MSN-Ed, RN, NPD-BC-marks the first successful antimicrobial textile trial of its kind to demonstrate statistically significant reductions in bacterial loads on scrubs worn in a real-world healthcare setting.\"Previous attempts using other antimicrobial chemistries have failed to produce results of this magnitude. This trial conclusively showed that scrubs treated with PROTX2® and PROTX2® combined with our ecoPEL™ Fluorine-Free Durable Water Repellent (DWR) technology achieved significant and quantifiable reductions in surface bacterial contamination compared to untreated scrubs-proof that these proprietary technologies can deliver infection control performance unmatched in the industry,\" said Giancarlo Beevis, President and CEO of IFTNA.\"This is an extraordinary moment for IFTNA. For decades, infection prevention experts have looked for textile-based solutions that could truly reduce bacterial contamination in real-world hospital environments. Until now, no trial has achieved this level of measurable infection control benefits,\" added Mr Beevis.\"I believe that this publication has the potential to draw the attention of some of the most respected leaders in infection prevention across the USA and globally and positions PROTX2® as a cornerstone solution in the fight against healthcare-associated infe...